Toggle Main Menu Toggle Search

ePrints

Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study

Lookup NU author(s): Dr Gill Hulme, Ian Dimmick, Dr Andrea Rossi, Professor John Simpson

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2018 The Author(s) Purpose: Cellular immune dysfunctions, which are common in intensive care patients, predict a number of significant complications. In order to effectively target treatments, clinically applicable measures need to be developed to detect dysfunction. The objective was to confirm the ability of cellular markers associated with immune dysfunction to stratify risk of secondary infection in critically ill patients. Methods: Multi-centre, prospective observational cohort study of critically ill patients in four UK intensive care units. Serial blood samples were taken, and three cell surface markers associated with immune cell dysfunction [neutrophil CD88, monocyte human leucocyte antigen-DR (HLA-DR) and percentage of regulatory T cells (Tregs)] were assayed on-site using standardized flow cytometric measures. Patients were followed up for the development of secondary infections. Results: A total of 148 patients were recruited, with data available from 138. Reduced neutrophil CD88, reduced monocyte HLA-DR and elevated proportions of Tregs were all associated with subsequent development of infection with odds ratios (95% CI) of 2.18 (1.00–4.74), 3.44 (1.58–7.47) and 2.41 (1.14–5.11), respectively. Burden of immune dysfunction predicted a progressive increase in risk of infection, from 14% for patients with no dysfunction to 59% for patients with dysfunction of all three markers. The tests failed to risk stratify patients shortly after ICU admission but were effective between days 3 and 9. Conclusions: This study confirms our previous findings that three cell surface markers can predict risk of subsequent secondary infection, demonstrates the feasibility of standardized multisite flow cytometry and presents a tool which can be used to target future immunomodulatory therapies. Trial registration: The study was registered with clinicaltrials.gov (NCT02186522).


Publication metadata

Author(s): Conway Morris A, Datta D, Shankar-Hari M, Stephen J, Weir CJ, Rennie J, Antonelli J, Bateman A, Warner N, Judge K, Keenan J, Wang A, Burpee T, Brown KA, Lewis SM, Mare T, Roy AI, Hulme G, Dimmick I, Rossi AG, Simpson AJ, Walsh TS

Publication type: Article

Publication status: Published

Journal: Intensive Care Medicine

Year: 2018

Volume: 44

Issue: 5

Pages: 627-635

Print publication date: 01/05/2018

Online publication date: 07/06/2018

Acceptance date: 02/04/2018

ISSN (print): 0342-4642

ISSN (electronic): 1432-1238

Publisher: Springer Verlag

URL: https://doi.org/10.1007/s00134-018-5247-0

DOI: 10.1007/s00134-018-5247-0


Altmetrics

Altmetrics provided by Altmetric


Actions

    Link to this publication


Share